Research Institute in Oncology and Hematology

Dr Marshall Pitz


Dr Marshall Pitz
675 McDermot Ave
Winnipeg, MB R3E 0V9
(204) 787-8776
Email: Dr Marshall Pitz M.D. FRCPC


As a medical oncologist and Chair of the Brain Tumour Disease Site Group at CancerCare Manitoba, Dr Pitz also has expertise is in clinical, epidemiology, and translational methods. He has worked on a number of retrospective reviews and translational programs in addition to serving as a member of the Brain Tumour Executive Committee and Investigational New Drug Executive Committee at the National Cancer Institute of Canada Clinical Trials Group.

Team Members

Publications Since 2010

PubMed Listed Publications
  1. High-grade glioma management and response assessment-recent advances and current challenges. Khan MN, Sharma AM, Pitz MW, Loewen SK, Quon H, Poulin A, Essig M. Curr Oncol. 2016 Aug;23(4):e383-91. doi: 10.3747/co.23.3082. Epub 2016 Aug 12. Review.

  2. Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells. Klonisch T, Glogowska A, Thanasupawat T, Burg M, Krcek J, Pitz MW, Jaggupilli A, Chelikani P, Wong GW, Hombach-Klonisch S. Br J Pharmacol. 2016 Jul 22. doi: 10.1111/bph.13559. [Epub ahead of print] Review.

  3. Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. Graham J, Pitz MW, Gordon V, Grenier D, Amir E, Niraula S. Cancer Treat Rev. 2016 Apr;45:1-6. doi: 10.1016/j.ctrv.2016.02.004. Epub 2016 Feb 22. Review.

  4. Personal exposure to ultrafine particles: Two-level statistical modeling of background exposure and time-activity patterns during three seasons. Deffner V, Küchenhoff H, Maier V, Pitz MW, Cyrys J, Breitner S, Schneider A, Gu J, Geruschkat U, Peters A. J Expo Sci Environ Epidemiol. 2016 Jan-Feb;26(1):17-25. doi: 10.1038/jes.2014.73. Epub 2014 Nov 19.

  5. Phase II study of PX-866 in recurrent glioblastoma. Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, Mason WP. Neuro Oncol. 2015 Sep;17(9):1270-4. doi: 10.1093/neuonc/nou365. Epub 2015 Jan 20.

  6. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. Bordun KA, Premecz S, daSilva M, Mandal S, Goyal V, Glavinovic T, Cheung M, Cheung D, White CW, Chaudhary R, Freed DH, Villarraga HR, Herrmann J, Kohli M, Ravandi A, Thliveris J, Pitz MW, Singal PK, Mulvagh S, Jassal DS. Am J Physiol Heart Circ Physiol. 2015 Aug 15;309(4):H692-701. doi: 10.1152/ajpheart.00172.2015. Epub 2015 Jun 19.

  7. Androgen pathway manipulation and survival in patients with lung cancer. Harlos C, Musto G, Lambert P, Ahmed R, Pitz MW. Horm Cancer. 2015 Jun;6(2-3):120-7. doi: 10.1007/s12672-015-0218-1. Epub 2015 Mar 20.\

  8. Antiestrogen use and survival of women with non-small cell lung cancer in Manitoba, Canada. Lother SA, Harding GA, Musto G, Navaratnam S, Pitz MW. Horm Cancer. 2013 Oct;4(5):270-6. doi: 10.1007/s12672-013-0149-7. Epub 2013 May 29.

  9. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Beiggi S, Johnston JB, Seftel MD, Pitz MW, Kumar R, Banerji V, Griffith EJ, Gibson SB. Br J Cancer. 2013 Sep 3;109(5):1287-90. doi: 10.1038/bjc.2013.381. Epub 2013 Jul 16.

  10. Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort. Pitz MW, Musto G, Navaratnam S. Can Respir J. 2013 Jan-Feb;20(1):30-4.

  11. Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma. Pitz MW, Lipson M, Hosseini B, Lambert P, Guilbert K, Lister D, Schroeder G, Jones K, Mihalicioiu C, Eisenstat DD. Curr Oncol. 2012 Dec;19(6):308-14. doi: 10.3747/co.19.1151.

  12. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. Pitz MW, Desai A, Grossman SA, Blakeley JO. J Neurooncol. 2011 Sep;104(3):629-38. doi: 10.1007/s11060-011-0564-y. Epub 2011 Mar 12. Review.

  13. Wait times from presentation to treatment for colorectal cancer: a population-based study. Singh H, De Coster C, Shu E, Fradette K, Latosinsky S, Pitz MW, Cheang M, Turner D. Can J Gastroenterol. 2010 Jan;24(1):33-9.

Research Funding

Mobile Access to Clinical Information
CancerCare Manitoba Foundation Infrastructure grant - $74 143.34
July 2015

The Role of Nerve Entrapment in Chemotherapy-Induced Peripheral Neuropathy and the Potential Role for Physical Therapy: Could a Dual Nerve Disorder be Responsible for Severity of Symptoms?
CancerCare Manitoba Foundation Operating grant - $88 155.50
July 2014 – June 2016

Lung cancer outcomes for patients taking androgen deprivation therapy
CancerCare Manitoba Foundation Operating grant - $30 651.28
July 2013

CancerCare Manitoba Research Day
CancerCare Manitoba Foundation Infrastructure Grant- $10 000
July 2010

Molecular correlates of outcome in patients with Glioblastoma Multiforme
Brain Tumour Foundation of Canada Operating Grant - $25 000
May 2010

Population-based analysis of trastuzumab use and outcomes in Manitoba
Manitoba Medical Services Foundation Operating Grant - $20 000

Establish personalized subtype and drug resistance signatures of glioblastoma
PI: Thomas Klonisch
Diagnostic Services Manitoba: $15 000
April 2015 – March 2016

Investigating Gender Differences in Lung Cancer Survival in Manitoba
PI: Rashid Ahmed
CancerCare Manitoba Foundation: $33 000
July 2014 – June 2015

Impact of treatment consultation recordings on cancer patient outcomes: A prospective, parallel, randomized controlled trial.
PI: Thomas Hack
Canadian Institutes of Health Research: $178 590
April 2013 – March 2016

Early Detection of Broken Hearts in Cancer Patients: Bevacizumab, Sunitinib, and Heart Failure
PI: Davinder Jassal
CANUSA Grant: $250 000
July 2012 – June 2014

Role of BNIP3 in Transcriptional Repression in Glioblastoma Multiforme
PI: Spencer Gibson
CancerCare Manitoba Foundation: $120 000
July 2010 – June 2012

RIOH gratefully acknowledges the generous support of

CCMB_Logo RIOH is a joint institute of CancerCare Manitoba and University of Manitoba UofM_Logo